| French national health authority recommendations for RBC and platelet transfusion: the “hot” topics |
Mauricette Michallet (France) |
| Haemovigilance in Europe: What do health authorities expect from haemovigilance? |
Deirdre Fehily (European Commission) |
| Haemovigilance lessons and perspectives from around the world |
Bernard Lassale (France) |
| Haemovigilance lessons and perspectives from around the world: Auristela |
Maciel Lins (Brazil) |
| How do we evaluate cost-effectiveness in transfusion and haemovigilance? |
Mart Janssen (The Netherlands) |
|
|
Tjerk van der Schaaf( (The Netherlands) |
| What can “Omics” bring to transfusion medicine? |
Michel Prudent (Switzerland) |
| Haemovigilance in Africa – South Africa |
Neo Moleli |
| Haemovigilance in Africa – Burkina Faso |
Salam Sawadogo |
| Abiyi Belay Ambaye (Haemovigilance in Africa – Ethiopia, Ghana) |
Michael Acquah |
| Laboratory surveys from UK Transfusion Laboratory Collaborative (UKTLC) confirm cause for concern. Joanne Bark (United Kingdom) |
|
|
|
|
| Hepatitis E – to screen or not to screen? Hans Zaaijer (The Netherlands) |
|
| Hepatitis E – to screen or not to screen? Lorna Williamson (United Kingdom) |
|
| Look-back studies to assess microbiological risks. Syria Laperche (France) |
|
| Changes in deferrals for MSM: implications for haemovigilance. Josiane Pillonel (France) |
|
| Detection and prevention of vasovagal reactions in blood donors. Mindy Goldman(Canada) |
|
| Young donors: assessing the risks. Peter Tomasulo (USA) |
|
| How to reduce delayed donor adverse reactions? Nuria Nomen Calvet (Spain) |
|
| Human factors and transfusion errors. Paula Bolton-Maggs (United Kingdom) |
|
|
|
|
|
|
|
| Hereditary haemochromatosis: implications for donors, products and patients. Gilles Follea (France) |
|
| Current concepts in iron metabolism relevant to transfusion and haemovigilance. Pierre Brissot (France) |
|
| Iron deficiency in donors: how to assess and prevent it? Kevin Land (USA) |
|
| Transfusional iron overload. Joan Cid (Spain) |
|
